In 2018, WHO recommended TCV to be prioritized in countries with the highest burden of typhoid disease or a
high burden of drug-resistant S. Typhi. TCVs are safe and effective vaccines that overcome many of the shortfalls of the previously available typhoid vaccines. WHO has prequalified two TCVs—Typbar TCV® and TYPHIBEV®— that are eligible for introduction support from Gavi, the Vaccine Alliance.